Published in Nat Genet on November 03, 2013
WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. J Clin Invest (2015) 1.68
Genomic spectra of biliary tract cancer. Nat Genet (2015) 1.58
Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. Sci Adv (2015) 1.33
Cholangiocarcinoma: molecular pathways and therapeutic opportunities. Semin Liver Dis (2014) 1.28
Oxidative stress and its significant roles in neurodegenerative diseases and cancer. Int J Mol Sci (2014) 1.22
The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther (2014) 1.21
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget (2014) 1.14
Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis. J Natl Cancer Inst (2014) 1.14
Schistosome and liver fluke derived catechol-estrogens and helminth associated cancers. Front Genet (2014) 1.10
Why does infection with some helminths cause cancer? Trends Cancer (2015) 1.04
Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann Surg Oncol (2014) 1.02
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Oncotarget (2015) 1.02
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol (2016) 0.96
Wnt signaling in cancer. Oncogene (2016) 0.95
Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet (2015) 0.94
Functional and genetic deconstruction of the cellular origin in liver cancer. Nat Rev Cancer (2015) 0.92
CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice. Proc Natl Acad Sci U S A (2015) 0.89
Mutation signatures of carcinogen exposure: genome-wide detection and new opportunities for cancer prevention. Genome Med (2014) 0.89
Cholangiocarcinoma: Current Knowledge and New Developments. Gut Liver (2016) 0.89
Genomic landscapes of breast fibroepithelial tumors. Nat Genet (2015) 0.88
Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated Cholangiocarcinoma. EBioMedicine (2016) 0.87
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. Oncotarget (2016) 0.87
Suppression of the SWI/SNF Component Arid1a Promotes Mammalian Regeneration. Cell Stem Cell (2016) 0.87
Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance. Genome Med (2015) 0.87
Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma. BMC Cancer (2015) 0.87
BAP1 hereditary cancer predisposition syndrome: a case report and review of literature. Biomark Res (2015) 0.80
Anti-Tumor Effects of Second Generation β-Hydroxylase Inhibitors on Cholangiocarcinoma Development and Progression. PLoS One (2016) 0.79
Somatic alteration and depleted nuclear expression of BAP1 in human esophageal squamous cell carcinoma. Cancer Sci (2015) 0.79
Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist (2016) 0.79
Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma. Medicine (Baltimore) (2016) 0.79
BRCA1-associated protein 1 (BAP1) deubiquitinase antagonizes the ubiquitin-mediated activation of FoxK2 target genes. J Biol Chem (2014) 0.79
Molecular diagnosis of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci (2014) 0.79
Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma. Curr Opin Gastroenterol (2015) 0.79
Emerging Molecular Therapeutic Targets for Cholangiocarcinoma. J Hepatol (2017) 0.78
Intratumoral heterogeneity of intrahepatic cholangiocarcinoma. Oncotarget (2017) 0.78
IDH mutations in liver cell plasticity and biliary cancer. Cell Cycle (2014) 0.77
Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma. PLoS One (2016) 0.77
Mutations of Chromatin Structure Regulating Genes in Human Malignancies. Curr Protein Pept Sci (2016) 0.76
Pathological characteristics of intraductal polypoid neoplasms of bile ducts in Thailand. Int J Clin Exp Pathol (2015) 0.76
Hepatocyte-Specific Arid1a Deficiency Initiates Mouse Steatohepatitis and Hepatocellular Carcinoma. PLoS One (2015) 0.76
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. Cancer Discov (2016) 0.76
The Chromatin Regulator BRPF3 Preferentially Activates the HBO1 Acetyltransferase but Is Dispensable for Mouse Development and Survival. J Biol Chem (2015) 0.76
Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines. Cancer Cell Int (2014) 0.76
Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. Cancer Metastasis Rev (2016) 0.76
Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma. Epigenetics (2016) 0.76
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. Cancer Discov (2017) 0.75
An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma. Int J Genomics (2015) 0.75
Parasite Infection, Carcinogenesis and Human Malignancy. EBioMedicine (2016) 0.75
Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer (2016) 0.75
Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors. Am J Cancer Res (2017) 0.75
Hypermutation and unique mutational signatures of occupational cholangiocarcinoma in printing workers exposed to haloalkanes. Carcinogenesis (2016) 0.75
Control of Wnt Receptor Turnover by R-spondin-ZNRF3/RNF43 Signaling Module and Its Dysregulation in Cancer. Cancers (Basel) (2016) 0.75
Liver cancer oncogenomics: opportunities and dilemmas for clinical applications. Hepat Oncol (2015) 0.75
Genetics: genetics of biliary tract cancer. Nat Rev Gastroenterol Hepatol (2013) 0.75
Therapeutic implication of HER2 in advanced biliary tract cancer. Oncotarget (2016) 0.75
Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans. Oncogenesis (2016) 0.75
Exploring the Mechanisms of Gastrointestinal Cancer Development Using Deep Sequencing Analysis. Cancers (Basel) (2015) 0.75
Receptor tyrosine kinase amplification is predictive of distant metastasis in patients with oral squamous cell carcinoma. Cancer Sci (2016) 0.75
CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment. Cancer Sci (2016) 0.75
A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. Sci Rep (2016) 0.75
TGFβ signaling: a friend or a foe to hepatic fibrosis and tumorigenesis. Ann Transl Med (2016) 0.75
Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. J Gastrointest Oncol (2016) 0.75
Moving upstream in the war on WNTs. J Clin Invest (2015) 0.75
Elevated prevalence of Helicobacter species and virulence factors in opisthorchiasis and associated hepatobiliary disease. Sci Rep (2017) 0.75
Von Hippel-Lindau status influences phenotype of liver cancers arising from PTEN loss. Gastrointest Cancer (2015) 0.75
Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations. Oncotarget (2016) 0.75
Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer. Sci Rep (2016) 0.75
Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy. Am J Cancer Res (2016) 0.75
The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine? J Gastrointest Oncol (2016) 0.75
Data on affected cancer-related genes in pediatric t(12;21)-positive acute lymphoblastic leukemia patients harboring unbalanced der(6)t(X;6) translocations. Data Brief (2016) 0.75
Targeting Angiogenesis in Biliary Tract Cancers: An Open Option. Int J Mol Sci (2017) 0.75
Germline BAP1 mutations induce a Warburg effect. Cell Death Differ (2017) 0.75
Immunotherapeutic Approaches to Biliary Cancer. Curr Treat Options Oncol (2017) 0.75
Genetic alterations in Japanese extrahepatic biliary tract cancer. Oncol Lett (2017) 0.75
Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Cancers (Basel) (2017) 0.75
Helminth infection-induced malignancy. PLoS Pathog (2017) 0.75
The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer. Therap Adv Gastroenterol (2017) 0.75
Emerging molecular targets and therapy for cholangiocarcinoma. World J Gastrointest Oncol (2017) 0.75
The Sequence Alignment/Map format and SAMtools. Bioinformatics (2009) 232.39
Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (2009) 190.94
Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A (2010) 7.70
Frequent mutation of BAP1 in metastasizing uveal melanomas. Science (2010) 7.47
SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer (2011) 6.87
The epidemiology of cholangiocarcinoma. Semin Liver Dis (2004) 5.59
Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature (2010) 5.23
BAP1 loss defines a new class of renal cell carcinoma. Nat Genet (2012) 4.97
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (2008) 3.95
Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet (2012) 3.63
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet (2011) 3.41
Risk factors for cholangiocarcinoma. Hepatology (2011) 3.27
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist (2011) 3.05
IMA: an R package for high-throughput analysis of Illumina's 450K Infinium methylation data. Bioinformatics (2012) 2.97
A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6. Bioinformatics (2009) 2.90
BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res (2008) 2.81
Analysis of the ARMD1 locus: evidence that a mutation in HEMICENTIN-1 is associated with age-related macular degeneration in a large family. Hum Mol Genet (2003) 2.72
Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol (2008) 2.44
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene (2012) 2.41
Regulation of intracellular pH by immortalized human intrahepatic biliary epithelial cell lines. Am J Physiol (1994) 2.36
Molecular architecture of quartet MOZ/MORF histone acetyltransferase complexes. Mol Cell Biol (2008) 1.89
The tumorigenic liver fluke Opisthorchis viverrini--multiple pathways to cancer. Trends Parasitol (2012) 1.86
ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov (2012) 1.81
Infection with liver flukes (Opisthorchis viverrini, Opisthorchis felineus and Clonorchis sinensis). IARC Monogr Eval Carcinog Risks Hum (1994) 1.71
TumorBoost: normalization of allele-specific tumor copy numbers from a single pair of tumor-normal genotyping microarrays. BMC Bioinformatics (2010) 1.70
Largest subunits of the human SWI/SNF chromatin-remodeling complex promote transcriptional activation by steroid hormone receptors. J Biol Chem (2002) 1.61
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene (2013) 1.55
Genomic profiles specific to patient ethnicity in lung adenocarcinoma. Clin Cancer Res (2011) 1.45
Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011. Leukemia (2013) 0.98
Microproteinuria during Opisthorchis viverrini infection: a biomarker for advanced renal and hepatobiliary pathologies from chronic opisthorchiasis. PLoS Negl Trop Dis (2013) 0.86
Angelman syndrome and severe infections in a patient with de novo 15q11.2-q13.1 deletion and maternally inherited 2q21.3 microdeletion. Gene (2012) 0.79
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Primer3--new capabilities and interfaces. Nucleic Acids Res (2012) 20.34
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics (2012) 8.61
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med (2012) 4.90
Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet (2012) 4.82
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Liver fluke induces cholangiocarcinoma. PLoS Med (2007) 3.89
Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet (2012) 3.63
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest (2010) 3.41
Phylogeographic reconstruction of a bacterial species with high levels of lateral gene transfer. BMC Biol (2009) 2.94
Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology (2009) 2.94
An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell (2011) 2.78
Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem (2008) 2.72
STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell (2012) 2.66
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res (2010) 2.61
Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA (2005) 2.59
Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology (2013) 2.46
Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol (2008) 2.44
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol (2009) 2.41
Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut (2012) 2.36
Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology (2011) 2.36
Genomic patterns of pathogen evolution revealed by comparison of Burkholderia pseudomallei, the causative agent of melioidosis, to avirulent Burkholderia thailandensis. BMC Microbiol (2006) 2.35
Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei. Emerg Infect Dis (2008) 2.24
Opisthorchiasis and Opisthorchis-associated cholangiocarcinoma in Thailand and Laos. Acta Trop (2010) 2.23
Opisthorchis viverrini: an underestimated parasite in world health. Trends Parasitol (2008) 2.21
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol (2011) 2.13
Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med (2013) 2.07
Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res (2011) 2.05
Ten-year results of thoracoscopic unilateral extended thymectomy performed in nonthymomatous myasthenia gravis. Ann Surg (2011) 2.03
An alternative approach to determining therapeutic choices in advanced non-small cell lung carcinoma (NSCLC): maximizing the diagnostic procedure and the use of low-volume lung biopsies. J Thorac Oncol (2007) 1.98
Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet (2009) 1.96
Preparing the "soil": the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res (2006) 1.94
Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol (2008) 1.87
Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. Clin Cancer Res (2011) 1.86
Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res (2010) 1.85
The airborne metagenome in an indoor urban environment. PLoS One (2008) 1.81
Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1. Proc Natl Acad Sci U S A (2012) 1.80
Gastrointestinal stromal tumors: retrospective analysis of the computer-tomographic aspects. J Gastrointestin Liver Dis (2007) 1.77
Cystic renal neoplasia following conditional inactivation of apc in mouse renal tubular epithelium. J Biol Chem (2004) 1.77
Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res (2008) 1.76
HRPT2 gene alterations in ossifying fibroma of the jaws. Oral Oncol (2006) 1.72
Genetic algorithms applied to multi-class prediction for the analysis of gene expression data. Bioinformatics (2003) 1.70
MicroRNA profiling of human kidney cancer subtypes. Int J Oncol (2009) 1.68
Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res (2007) 1.66